Dr. Jeffrey H. William, M.D.
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Medical school
- Tufts University School of Medicine (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 423
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Tufts University School of Medicine
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
MA license 252503 -
Internal Medicine Physician
MA license 244088
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Beth Israel Deaconess Medical Center Boston, MA
- Beth Israel Deaconess Hospital - Needham Needham, MA
- Beth Israel Deaconess Hospital - Milton Milton, MA
Medical groups
- Harvard Medical Faculty Phys at Beth Israel Deaconess Med Ctr Inc (1,740 clinicians)
- Atrius Health Inc (1,222 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 423
- Services billed
- 3,645
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 344 | 240 |
| Insertion of needle into vein for collection of blood sample | 236 | 115 |
| Creatinine level to test for kidney function or muscle injury | 232 | 126 |
| Magnesium level | 217 | 115 |
| Urine microalbumin (protein) level | 216 | 123 |
| Parathormone (parathyroid hormone) level | 198 | 106 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 195 | 93 |
| Phosphate level | 184 | 109 |
| Urea nitrogen level to assess kidney function, quantitative | 165 | 91 |
| Blood test panel for electrolytes (sodium potassium, chloride, carbon dioxide) | 158 | 86 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Calcitriol Other prescribers in Boston, MA | 217 |
| Losartan Potassium Other prescribers in Boston, MA | 131 |
| Amlodipine Besylate Other prescribers in Boston, MA | 101 |
| Lisinopril Other prescribers in Boston, MA | 98 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Boston, MA | 76 |
| Jardiance (empagliflozin) Other prescribers in Boston, MA | 73 |
| Sevelamer Carbonate Other prescribers in Boston, MA | 69 |
| Torsemide Other prescribers in Boston, MA | 57 |
| Spironolactone Other prescribers in Boston, MA | 46 |
| Potassium Citrate Er (potassium citrate) Other prescribers in Boston, MA | 34 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 8 payments worth $25.63 in total to this clinician.
| Travere Therapeutics, Inc. | $25.63 |
|---|
| Education | $25.63 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Travere Therapeutics, Inc. Nov 18, 2025 | Education Filspari · Kidney Disease · in-kind | $11.77 |
| Travere Therapeutics, Inc. Aug 28, 2025 | Education Thiola · Kidney Stones · in-kind | $3.01 |
| Travere Therapeutics, Inc. Aug 28, 2025 | Education Thiola · Kidney Stones · in-kind | $2.55 |
| Travere Therapeutics, Inc. May 15, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Nov 6, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Nov 18, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Dec 12, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
| Travere Therapeutics, Inc. Dec 18, 2025 | Education Filspari · Kidney Disease · in-kind | $1.66 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $12,500 in research payments for these studies, mostly to the institutions running them.
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.